<DOC>
	<DOCNO>NCT02059642</DOCNO>
	<brief_summary>This study multisite , randomize , double-blind , placebo-controlled , phase 2/3 study MG01CI ( 1400 mg daily ) 6 week compare placebo 1:1 ratio 300 adult ADHD .</brief_summary>
	<brief_title>A 6 Week Study MG01CI 1400 mg Compared With Placebo Adults With ADHD ( Attention Deficit/Hyperactivity )</brief_title>
	<detailed_description>This study multisite , randomize , double-blind , placebo-controlled , phase 2/3 study MG01CI ( 1400 mg daily ) 6 week compare placebo 1:1 ratio 300 adult ADHD . The study comprise Screening Visit initial assessment make Washout Period prospective subject must discontinue ADHD medication 14 day ( psychotropic medication fluoxetine ) 28 day ( fluoxetine ) randomization study . The Washout Period 14 day , may extend 28 day fluoxetine washout . Subjects require either 14-day 28-day Washout Period Interim Visit ( drug ) Day -8 ( Day -10 Day -3 ) CAARS-Inv assessment Washout Period . The Baseline CAARS Inv assessment conduct Day 0 . If ≥25 % change CAARS-Inv result Interim Visit ( drug ) assessment Baseline assessment , subject return Baseline CAARS-Inv assessment , subject randomize . For subject need washout , ≥25 % change CAARS-Inv result Screening Visit assessment Baseline assessment , subject return Baseline CAARS-Inv assessment , subject randomize . Following Washout Period require washout , follow Screening Visit subject require washout , eligible subject undergo baseline assessment randomize Day 0 MG01CI 1400 mg match placebo begin Double-blind Treatment Period . The Double-blind Treatment Period 6 week duration . There 2-week Follow-up Period last dose study treatment early termination .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>Subject man nonpregnant , nonlactating woman 18 55 year age , inclusive , Screening Visit . Subject diagnosis ADHD base criterion Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIV ) DSM5 . Subject ADHD least moderate clinical severity ( Clinical Global ImpressionSeverity [ CGIS ] ) score 4 great ) . Subject score total ADHD symptom score adult prompt CAARSInv least 22 . Female subject childbearing potential must agree use effective contraceptive throughout study Subject able attend clinic regularly reliably . Subject able swallow tablet capsule . Subject able understand , read , write , speak English fluently complete studyrelated material ( Hebrew Israeli subject ) . Subject able understand sign inform consent form participate study . Subject respond past 2 adequate trial stimulant treatment 1 adequate trial atomoxetine treatment ( investigator 's judgment ) . Subject psychiatric condition clinically significant unstable medical surgical condition may preclude safe complete study participation determine investigator . Subject know suspected human immune deficiency viruspositive status disease acquire immunodeficiency disorder , hepatitis C , hepatitis B , tuberculosis . Subject history allergy sensitivity Bcomplex vitamin . Subject history intellectual disability history suspicion autism spectrum disorder . Subject current Axis I diagnosis ( ADHD ) accord Structured Clinical Interview DSM IV Axis I Disorders ( SCID ) lifetime history bipolar disorder psychosis . Subject use megadose vitamin B6/pyridoxine 28 day Screening Visit . Subject use highdose supplement omega3 fatty acid ≥ 500 mg least 1 day folic acid supplement 2 week Screening Visit . Subject use investigational medication/treatment 30 day Screening Visit Subject use medication food supplement investigator medical monitor considers unacceptable 14day period randomization . Subject current drug alcohol dependence substance abuse disorder accord DSMIV . Subject also agree keep caffeine intake consistent refrain consume ≥300 mg per day caffeine ( three 8ounce serving coffee ) study . Subject suicidality , define active ideation , intent plan , significant lifetime suicidal behavior . Subjects exhibit history ( within previous 12 month ) nonsuicidal selfinjurious behavior exclude . Subject take prescription nonprescription ADHD medication 14 day ( psychotropic medication fluoxetine ) 28 day ( fluoxetine ) randomization visit . Subject significantly visually impaired extent able correct prescription glass contact lens Subject relate sponsor , investigator , study staff . Subject condition , principal investigator 's opinion , would place subject risk influence conduct study interpretation result , Subject fully comprehend implication protocol , comply requirement , incapable follow study schedule reason . Subject pregnant , lactating , use inadequate contraceptive method . If ≥25 % change CAARSInv result Interim visit ( drug ) assessment Baseline assessment , subject return Baseline CAARSInv assessment , subject randomize . For subject need washout , ≥25 % change CAARSInv result Screening Visit assessment Baseline assessment , subject return Baseline CAARSInv assessment , subject randomize .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>